The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Pharmacokinetics, Brain Delivery, and Efficacy in Brain Tumor-Bearing Mice of Glutathione Pegylated Liposomal Doxorubicin (2B3-101)
Open accessAbstract
Brain cancer is a devastating disease affecting many people worldwide. Effective treatment with chemotherapeutics is limited due to the presence of the blood-brain barrier (BBB) that tightly regulates the diffusion of endogenous molecules but also xenobiotics. Glutathione pegylated liposomal doxorubicin (2B3-101) is being developed as a new treatment option for patients with brain cancer. It is based on already marketed pegylated liposomal doxorubicin (Doxil®/Caelyx®), with an additional glutathione coating that safely enhances drug delivery across the BBB. Uptake of 2B3-101 by human brain capillary endothelial cells in vitro was time-, concentration- and temperature-dependent, while pegylated liposomal doxorubicin mainly remained bound to the cells. In vivo, 2B3-101 and pegylated liposomal doxorubicin had a comparable plasma exposure in mice, yet brain retention 4 days after administration was higher for 2B3-101. 2B3-101 was overall well tolerated by athymic FVB mice with experimental human glioblastoma (luciferase transfected U87MG). In 2 independent experiments a strong inhibition of brain tumor growth was observed for 2B3-101 as measured by bioluminescence intensity. The effect of weekly administration of 5 mg/kg 2B3-101 was more pronounced compared to pegylated liposomal doxorubicin (p<0.05) and saline (p<0.01). Two out of 9 animals receiving 2B3-101 showed a complete tumor regression. Twice-weekly injections of 5 mg/kg 2B3-101 again had a significant effect in inhibiting brain tumor growth (p<0.001) compared to pegylated liposomal doxorubicin and saline, and a complete regression was observed in 1 animal treated with 2B3-101. In addition, twice-weekly dosing of 2B3-101 significantly increased the median survival time by 38.5% (p<0.001) and 16.1% (p<0.05) compared to saline and pegylated liposomal doxorubicin, respectively. Overall, these data demonstrate that glutathione pegylated liposomal doxorubicin enhances the effective delivery of doxorubicin to brain tumors and could become a promising new therapeutic option for the treatment of brain malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“using active doxorubicin loading against an ammonium sulfate gradient [32].”
MethodO’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Blood‐brain barrier‐specific properties of a human adult brain endothelial cell line
Weksler, B. B., Subileau, E. A., Perrière, N., Charneau, P., Holloway, K., Leveque, M., Tricoire‐Leignel, H., Nicotra, A., Bourdoulous, S., Turowski, P., et al. (2005) · The FASEB Journal · doi:10.1096/fj.04-3458fje · Cited by 1,330
Régina, A., Demeule, M., Ché, C., Lavallée, I., Poirier, J., Gabathuler, R., Béliveau, R., & Castaigne, J. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.260 · Cited by 368
de Boer, A. G., & Gaillard, P. J. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105237 · Cited by 348
Self-citationBlock, K. I., Koch, A. C., Mead, M. N., Tothy, P. K., Newman, R. A., & Gyllenhaal, C. (2008) · International Journal of Cancer · doi:10.1002/ijc.23754 · Cited by 328
Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated Efflux
Dai, H., Marbach, P., Lemaire, M., Hayes, M., & Elmquist, W. F. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045260 · Cited by 273
Aryal, M., Vykhodtseva, N., Zhang, Y.-Z., Park, J., & McDannold, N. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.04.007 · Cited by 261
Siegal, T., Horowitz, A., & Gabizon, A. (1995) · Journal of neurosurgery · doi:10.3171/jns.1995.83.6.1029 · Cited by 232
The role of the organ microenvironment in brain metastasis
Fidler, I. J. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2010.12.009 · Cited by 217
New strategies to deliver anticancer drugs to brain tumors
Laquintana, V., Trapani, A., Denora, N., Wang, F., Gallo, J. M., & Trapani, G. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903167942 · Cited by 214
Gliadel Wafers in the Treatment of Malignant Glioma: A Systematic Review
Perry, J., Chambers, A., Spithoff, K., Laperriere, N., & on behalf of the Neuro-Oncology Disease Site Group§ of Cancer Care Ontario’s Program in Evidence-Based Care (2007) · Current Oncology · doi:10.3747/co.2007.147 · Cited by 212
Pegylated liposomal doxorubicin‐efficacy in patients with recurrent high‐grade glioma
Hau, P., Fabel, K., Baumgart, U., Rümmele, P., Grauer, O., Bock, A., Dietmaier, C., Dietmaier, W., Dietrich, J., Dudel, C., et al. (2004) · Cancer · doi:10.1002/cncr.20073 · Cited by 196
Gaillard, P. J., Appeldoorn, C. C. M., Rip, J., Dorland, R., van der Pol, S. M. A., Kooij, G., de Vries, H. E., & Reijerkerk, A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.022 · Cited by 191
Self-citationTardi, P., Boman, N., & Cullis, P. (1996) · Journal of Drug Targeting · doi:10.3109/10611869609015970 · Cited by 184
Kurzrock, R., Gabrail, N., Chandhasin, C., Moulder, S., Smith, C., Brenner, A., Sankhala, K., Mita, A., Elian, K., Bouchard, D., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0566 · Cited by 168
Gururaj Joshi, A., Aluise, C. D., Cole, M. P., Rukhsana Sultana, A., Pierce, W. M. J., Vore, M. E., Clair, D. K. S., & Butterfield, D. A. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.01.021 · Cited by 166
Evidence for carrier-mediated transport of glutathione across the blood-brain barrier in the rat.
Kannan, R., Kuhlenkamp, J. F., Jeandidier, E., Trinh, H., Ookhtens, M., & Kaplowitz, N. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114666 · Cited by 165
Klerk, C. P. W., Overmeer, R. M., Niers, T. M. H., Versteeg, H. H., Richel, D. J., Buckle, T., Noorden, C. J. F. V., & van Tellingen, O. (2007) · BioTechniques · doi:10.2144/000112515 · Cited by 164
Agarwal, S., Manchanda, P., Vogelbaum, M. A., Ohlfest, J. R., & Elmquist, W. F. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048322 · Cited by 163
Blood–brain barrier and chemotherapeutic treatment of brain tumors
de Vries, N. A., Beijnen, J. H., Boogerd, W. J., & van Tellingen, O. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.8.1199 · Cited by 156
The Biology of Metastasis to a Sanctuary Site
Palmieri, D., Chambers, A. F., Felding‐Habermann, B., Huang, S., & Steeg, P. S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2659 · Cited by 156
Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin
Fabel, K., Dietrich, J., Hau, P., Wismeth, C., Winner, B., Przywara, S., Steinbrecher, A., Ullrich, W., & Bogdahn, U. (2001) · Cancer · doi:10.1002/1097-0142(20011001)92:7<1936::aid-cncr1712>3.0.co;2-h · Cited by 155
Local delivery of doxorubicin for the treatment of malignant brain tumors in rats.
Lesniak, M. S., Upadhyay, U. M., Goodwin, R. M., Tyler, B., & Brem, H. (2005) · PubMed · Cited by 152
Chemosensitivity of glioma cells in vitro: a meta analysis
Wolff, J. E. A., Trilling, T., Mölenkamp, G., Egeler, R. M., & Jürgens, H. (1999) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050305 · Cited by 147
Ché, C., Yang, G., Thiot, C., Lacoste, M.-C., Currie, J.-C., Demeule, M., Régina, A., Béliveau, R., & Castaigne, J.-P. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm9016637 · Cited by 123
Lindqvist, A., Rip, J., Gaillard, P. J., Björkman, S. E., & Hammarlund‐Udenaes, M. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300272a · Cited by 106
Self-citationKannan, R., Chakrabarti, R., Tang, D., Kim, K. J., & Kaplowitz, N. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02184-8 · Cited by 99
Lu‐Emerson, C., & Eichler, A. F. (2012) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000413659.12304.a6 · Cited by 96
Anders, C. K., Adamo, B., Karginova, O. A., Deal, A. M., Rawal, S., Darr, D. B., Schorzman, A. N., Santos, C., Bash, R., Kafri, T., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061359 · Cited by 88
Intratumoral Doxorubicin in Patients With Malignant Brain Gliomas
Voulgaris, S., Partheni, M., Karamouzis, M. V., Dimopoulos, P., Papadakis, N., & Kalofonos, H. P. (2002) · American Journal of Clinical Oncology · doi:10.1097/00000421-200202000-00013 · Cited by 84
Arnold, R. D., Mager, D. E., Slack, J. E., & Straubinger, R. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1365 · Cited by 69
Evidence for Transcapillary Transport of Reduced Glutathione in Vascular Perfused Guinea-Pig Brain
Zloković, B. V., Mačkić, J. B., McComb, J. G., Weiss, M. H., Kaplowitz, N., & Kannan, R. (1994) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1994.1715 · Cited by 63
Uptake of Adriamycin in tumour and surrounding brain tissue in patients with malignant gliomas
von Holst, H., Knochenhauer, E., Blomgren, H., Collins, V. P., Ehn, L., Lindquist, M., Norén, G., & Peterson, C. (1990) · Acta Neurochirurgica · doi:10.1007/bf01842886 · Cited by 62
The role of chemotherapy in the treatment of patients with brain metastases from solid tumors
Walbert, T., & Gilbert, M. R. (2009) · International Journal of Clinical Oncology · doi:10.1007/s10147-009-0916-1 · Cited by 61
Eichler, A. F., & Plotkin, S. R. (2008) · Current Treatment Options in Neurology · doi:10.1007/s11940-008-0033-x · Cited by 61
Brain Drug Development and Brain Drug Targeting
Pardridge, W. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9387-0 · Cited by 59
Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies
Kemper, E. M., Leenders, W. P. J., Küsters, B., Lyons, S. K., Buckle, T., Heerschap, A., Boogerd, W. J., Beijnen, J. H., & van Tellingen, O. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.07.013 · Cited by 51
Enhanced brain drug delivery: safely crossing the blood–brain barrier
Gaillard, P. J., Visser, C. C., Appeldoorn, C. C. M., & Rip, J. (2011) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2011.12.002 · Cited by 50
Self-citationPegylated Liposomal Doxorubicin in Recurrent Malignant Glioma: Analysis of a Case Series
Glas, M., Koch, H., Hirschmann, B., Jauch, T., Steinbrecher, A., Herrlinger, U., Bogdahn, U., & Hau, P. (2007) · Oncology · doi:10.1159/000113052 · Cited by 30
Blood-to-Brain Drug Delivery Using Nanocarriers
Gaillard, P. J., Visser, C. C., de Boer, M., Appeldoorn, C. C. M., & Rip, J. (2013) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-9105-7_15 · Cited by 27
Self-citationReceptor-mediated delivery of drugs across the blood-brain barrier
Pieter, G. (2010) · Frontiers in Pharmacology · doi:10.3389/conf.fphar.2010.02.00025 · Cited by 14
Cited by
Liposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,156
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Current Challenges and Opportunities in Treating Glioblastoma
Shergalis, A., Bankhead, A., Luesakul, U., Muangsin, N., & Neamati, N. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014944 · Cited by 849
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Kciuk, M., Gielecińska, A., Mujwar, S., Kołat, D., Kałuzińska-Kołat, Ż., Celik, I., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040659 · Cited by 810
Hersh, A. M., Alomari, S., & Tyler, B. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084153 · Cited by 478
Metadata
- Authors
- Gaillard, P. J., Appeldoorn, C. C. M., Dorland, R., van Kregten, J., Manca, F., Vugts, D. J., Windhorst, B., van Dongen, G. A. M. S., de Vries, H. E., Maussang, D., & van Tellingen, O.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-01-08
- Volume
- 9
- Issue
- 1
- Pages
- e82331
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2037571189
- Cited by
- 273
- References
- 43
- FWCI
- 8.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.